2021
P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).
Schuetze S, Ballman K, Ganjoo K, Davis E, Morgan J, Tinoco G, Burgess M, Van Tine B, Choy E, Shepard D, Kelly C, Riedel R, von Mehren M, Siontis B, Attia S, Schwartz G, Deshpande H, Kozlowski E, Chen H, Rubin B. P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE). Journal Of Clinical Oncology 2021, 39: 11503-11503. DOI: 10.1200/jco.2021.39.15_suppl.11503.Peer-Reviewed Original ResearchObjective response ratePhase 2 trialEpithelioid hemangioendotheliomaObjective responseLarge prospective clinical studiesGI adverse effectsMetastatic epithelioid hemangioendotheliomaObjective tumor progressionPrimary trial endpointNausea/vomitingWeeks of therapyBiomarkers of inflammationProspective clinical studyTreatment of patientsClinical Trials NetworkCommon AEsMedian PFSOS ratesPt ageStable diseasePain scoresAdverse eventsMetastatic diseasePain intensityIndolent growth
2018
An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E, Deshpande H, Stein S. An update of lanreotide acetate for treatment of adults with carcinoid syndrome. Drugs Of Today 2018, 54: 457-465. PMID: 30209440, DOI: 10.1358/dot.2018.54.8.2834461.Peer-Reviewed Original ResearchConceptsSymptoms of carcinoid syndromeCarcinoid syndromeCarcinoid tumorsOrigin of carcinoid tumorsTreatment of carcinoid syndromeUrinary 5-hydroxyindoleacetic acidAdvanced metastatic diseaseSomatostatin analogue octreotideTreatment of adultsMetastatic diseaseSerotonin metaboliteAnalogue octreotideNative somatostatinDebilitating diarrheaLanreotide acetateSyndromeTumorSymptom controlLanreotideSlow-growingSymptomsSomatostatinTreatmentHalf-lifeChemotherapy
2011
Medullary thyroid cancer in the past, present and future: from bench to bedside
Deshpande H, Morgensztern D, Sosa J. Medullary thyroid cancer in the past, present and future: from bench to bedside. Expert Review Of Endocrinology & Metabolism 2011, 6: 585-597. DOI: 10.1586/eem.11.44.Peer-Reviewed Original ResearchMedullary thyroid cancerThyroid cancerManagement of MTCMaximum survival benefitSystemic treatment optionsHigh-volume surgeonsMultiple endocrine neoplasiaFirst clinical descriptionRET proto-oncogeneMetastatic diseaseSurvival benefitProphylactic thyroidectomyTreatment optionsSpecialized centersEndocrine neoplasiaClinical descriptionPatientsCancerDiseaseDiagnosisProto-oncogeneImportant advancesThyroidectomyComplicationsSurgery